In a multiomics analysis of 21 types of cancer, including prostate adenocarcinoma, a study found that the best indicator, out of 36 variables, to anti-PD-1/PD-L1 therapy was CD8+ T-cell abundance in the tumour [64]. This evidence concerns the gene CD8A and cancer.